Retavase
Active Ingredient(s): Reteplase, r-PAFDA Approved: * October 30, 1996
Pharm Company: * CENTOCOR INC
Category: Blood Thinner (Anticoagulant)
Reteplase, trade names include Retavase, is a thrombolytic drug, used to treat heart attacks by breaking up the clots that cause them. Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, which has been modified to contain 357 of the 527 amino acids of the original protein. It is produced in the bacterium Escherichia coli.[citation needed] Reteplase was approved for use in 1996.[1] Reteplase is similar to recombinant human tis... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.